Per-Olof Lundgren

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Patients Undergoing

Radical Prostatectomy

Radiofrequency Ablation

Top Venues

Current oncology (Toronto, Ont.)

The Journal of urology

International journal of molecular sciences

BJU international

This page only lists publications with an associated author ORCID identifier.

Publications

Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications. Current oncology (Toronto, Ont.) 31 (2) (2024)
Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications. Current oncology (Toronto, Ont.) 31 (2) (2024)
Anna Thor, Mette Pernille Myklebust, Anna Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, Olav Dahl, Anders Kjellman
miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study. The Journal of urology (2024)
Anna Thor, Mette Pernille Myklebust, Anna Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, Olav Dahl, Anders Kjellman
miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study. The Journal of urology (2024)
Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications. Current oncology (Toronto, Ont.) 31 (2) (2024)
Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications. Current oncology (Toronto, Ont.) 31 (2) (2024)
Anna Thor, Mette Pernille Myklebust, Anna Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, Olav Dahl, Anders Kjellman
miR-371a-3p Predicting Viable Tumor in Patients Undergoing RPLND for Metastatic Testicular Cancer: The SWENOTECA-MIR Study. The Journal of urology (2024)
Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications. Current oncology (Toronto, Ont.) 31 (2) (2024)
Jari Radros, Anders Kjellman, Lars Henningsohn, Yngve Forslin, Martin Delle, Marianna Hrebenyuk, Anna Thor, Tomas Thiel, Maria Hermann, Per-Olof Lundgren
Ablative or Surgical Treatment for Small Renal Masses (T1a): A Single-Center Comparison of Perioperative Morbidity and Complications. Current oncology (Toronto, Ont.) 31 (2) (2024)
Bernhard Tribukait, Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Claes R Nyman, Kiran Jagarlmundi, Ove Gustafsson
Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. International journal of molecular sciences 24 (6) (2023)
Bernhard Tribukait, Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Claes R Nyman, Kiran Jagarlmundi, Ove Gustafsson
Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. International journal of molecular sciences 24 (6) (2023)
Bernhard Tribukait, Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Claes R Nyman, Kiran Jagarlmundi, Ove Gustafsson
Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. International journal of molecular sciences 24 (6) (2023)
Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Ove Gustafsson
Reply to the letter by Ferraro and Biganzoli. BJU international 129 (3) (2022)
Per-Olof Lundgren, Bernhard Tribukait, Anders Kjellman, Ulf Norming, Kiran Jagarlmudi, Ove Gustafsson
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer. The Prostate 82 (8) (2022)
Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Ove Gustafsson
Association between one-time prostate-specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30-year prospective cohort study. BJU international 128 (4) (2021)
Per-Olof Lundgren, Anders Kjellman, Ulf Norming, Ove Gustafsson
Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study. The Prostate 80 (10) (2020)